首页> 外文期刊>Molecular cancer therapeutics >6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer.
【24h】

6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer.

机译:特定的谷胱甘肽S-转移酶抑制剂6-(7-硝基-2,1,3-苯并恶二唑-4-基硫基)己醇克服了小细胞肺癌中与多药耐药性(MDR)相关的蛋白1介导的MDR。

获取原文
获取原文并翻译 | 示例
           

摘要

In the present work, we have investigated the antitumor activity of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on aggressive small cell lung cancer. NBDHEX not only is cytotoxic toward the parental small cell lung cancer H69 cell line (LC(50) of 2.3 +/- 0.6 micromol/L) but also overcomes the multidrug resistance of its variant, H69AR, which overexpresses the ATP-binding cassette transporter multidrug resistance-associated protein 1 (MRP1; LC(50) of 4.5 +/- 0.9 micromol/L). Drug efflux experiments, done in the presence of a specific inhibitor of MRP1, confirmed that NBDHEX is not a substrate for this export pump. Interestingly, NBDHEX triggers two different types of cell death: a caspase-dependent apoptosis in the H69AR cells and a necrotic phenotype in the parental H69 cells. The apoptotic pathway triggered by NBDHEX in H69AR cells is associated with c-Jun NH(2)-terminal kinase and c-Jun activation, whereas glutathione oxidation and activation of p38(MAPK) is observed in the NBDHEX-treated H69 cells. In contrast to the parental cells, the higher propensity to die through apoptosis of the H69AR cell line may be related to the lower expression of the antiapoptotic protein Bcl-2. Therefore, down-regulation of a factor crucial for cell survival makes H69AR cells more sensitive to the cytotoxic action of NBDHEX, which is not a MRP1 substrate. We have previously shown that NBDHEX is cytotoxic toward P-glycoprotein-overexpressing tumor cell lines. Therefore, NBDHEX seems a very promising compound in the search for new molecules able to overcome the ATP-binding cassette family of proteins, one of the major mechanisms of multidrug resistance in cancer cells.
机译:在目前的工作中,我们已经研究了6-(7-硝基-2,1,3-苯并恶二唑-4-基硫基)己醇(NBDHEX)对侵袭性小细胞肺癌的抗肿瘤活性。 NBDHEX不仅对亲代小细胞肺癌H69细胞系(LC(50)为2.3 +/- 0.6 micromol / L)具有细胞毒性,而且克服了其变体H69AR的多药耐药性,后者过表达ATP结合盒转运蛋白多药耐药相关蛋白1(MRP1; LC(50)为4.5 +/- 0.9 micromol / L)。在特定的MRP1抑制剂存在下进行的药物外排实验证实NBDHEX不是该出口泵的底物。有趣的是,NBDHEX触发两种不同类型的细胞死亡:H69AR细胞中依赖胱天蛋白酶的凋亡和亲本H69细胞中坏死的表型。 NBDHEX在H69AR细胞中触发的凋亡途径与c-Jun NH(2)-末端激酶和c-Jun激活相关,而在NBDHEX处理的H69细胞中观察到谷胱甘肽氧化和p38(MAPK)的激活。与亲代细胞相反,H69AR细胞系通过凋亡而死亡的倾向较高可能与抗凋亡蛋白Bcl-2的较低表达有关。因此,对细胞存活至关重要的因子的下调使H69AR细胞对NBDHEX(不是MRP1底物)的细胞毒性作用更加敏感。先前我们已经证明NBDHEX对过表达P-糖蛋白的肿瘤细胞系具有细胞毒性。因此,NBDHEX在寻找能够克服蛋白质ATP结合盒家族的新分子方面似乎是非常有前途的化合物,这是癌细胞中多药耐药性的主要机制之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号